Cartesian Therapeutics Overview
Valuation check: RNAC's PEG ratio is 10.95, above the Healthcare sector average of 1.26.
Get informed when a big investor buys or sells
+ Follow10.95
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Cartesian Therapeutics (RNAC) currently reports a PEG ratio of 10.95. That is above the Healthcare sector average of 1.26. Use the charts on this page to explore Cartesian Therapeutics's PEG ratio history and peer comparisons.
Cartesian Therapeutics's PEG ratio of 10.95 is higher than the Healthcare sector average of 1.26. That is roughly 770.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Cartesian Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 10.95, RNAC can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 10.95, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 1.26. From there, open related valuation or income-statement pages for Cartesian Therapeutics, and consider following RNAC for alerts when major investors trade the stock.
Cartesian Therapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows 10.95 versus a sector average near 1.26. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNAC with unrelated industries.
